Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

36 results about "Refractory epilepsy" patented technology

Refractory epilepsy is a seizure disorder that resists drug treatment. There is some debate among clinicians and researchers about how to define refractory epilepsy.

Computational tool for pre-surgical evaluation of patients with medically refractory epilepsy

A method of identifying an epileptogenic zone of a brain includes receiving a plurality of electrical signals from a plurality of surgically implanted electrodes, calculating components of an adjacency matrix, calculating eigenvectors from the adjacency matrix, and selecting an eigenvector having a largest eigenvalue. The method includes assigning an integer rank to each component of the eigenvector, sliding the time window by a time increment and repeating the immediately preceding steps a plurality of times. The method includes normalizing each rank signal, extracting a multidimensional feature vector from each normalized signal, projecting each multidimensional feature vector onto a reduced dimensionality space, and receiving a plurality of training data points represented in the reduced dimensionality space. The method includes calculating grid weights for each feature vector, and assigning a numerical value to each electrode as an indication of whether the electrode is in an epileptogenic zone of the brain.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1

3-acylamino-N-arylbenzamide compound as well as preparation and application thereof

InactiveCN108864038AGood treatment effectReduce the number of spontaneousNervous disorderOrganic chemistryEpilepsy treatmentPentylenetetrazol
The invention provides a 3-acylamino-N-arylbenzamide compound and pharmaceutically acceptable salt thereof. The synthesis of the compound is divided into different synthetic blocks by adopting a convergent synthetic route and a target compound can be quickly prepared in batches through docking combination. The experiment proves that the compound provided by the invention has the advantages that the epileptic seizure latency induced by pentylenetetrazol can be significantly prolonged and the grade and mortality rate of epileptic seizures are reduced; a threshold of epileptic seizure induced bymaximum electroshock can be significantly increased and the mortality rate is reduced; in addition, a seizure threshold of refractory epilepsy can be obviously increased; besides, no obvious toxic orside effects are found, which indicates that the 3-acylamino-N-arylbenzamide compound can relieve or control epileptic seizures or even has a certain therapeutic effect on the refractory epilepsy which cannot be effectively treated by traditional drugs, so that the compound can be applied to the preparation of antiepileptic drugs. The compound disclosed by the invention has the advantages of easily-obtained raw materials for synthesizing, simple operation, high process scalability, suitability for industrial production and capability of providing a novel drug for epilepsy treatment. The structure of a general formula I is shown in the description.
Owner:ZHEJIANG UNIV

Pharmaceutical preparation for treating intractable epilepsy

InactiveCN113018386AStrong targetingDefine Quantitative RequirementsNervous disorderHydroxy compound active ingredientsCannabis sativa plantDisease
The invention discloses a pharmaceutical preparation for treating intractable epilepsy, the preparation comprises a cannabis sativa extract, a gastrodia elata extract, succinylated protein, borneol and an auxiliary agent, the active ingredient of the cannabis sativa extract is a compound with an alkyl resorcinol structure, and the active ingredient of the gastrodia elata extract is a compound with an alkyl resorcinol structure. As an extraction substance which is extracted from a cannabis sativa plant and has the same biological activity, the pharmaceutical preparation has a great synergistic effect on playing a pharmacological effect on refractory epilepsy, and the pharmacological activity of the pharmaceutical preparation is effectively improved; the gastrodia elata extract can provide effective nutrition and repair nerves in the brain, and the borneol can be used as a channel guiding drug to enhance absorption of other drugs in a blood brain barrier and effectively relieve convulsion, spasm, unconsciousness, wandering and other clinical characteristics accompanied by epilepsy disease attack, the succinylated protein in the preparation can prevent the drug from being damaged in an acid environment, and the nano-emulsion preparation prepared by adding the succinylated protein can effectively improve the bioavailability and stability of the drug.
Owner:黑龙江汉普康制药有限公司

A kind of scorpion venom heat-resistant synthetic peptide and use thereof

The invention discloses a scorpion venom heat-resistant synthetic peptide and its application, belonging to the field of polypeptide drug research and development. The polypeptide of the present invention is the amino acid sequence of the scorpion venom heat-resistant peptide (SVHRP) detected from the venom of the traditional Chinese medicine East Asian scorpion scorpion (BmK). A sample of the heat-resistant peptide extract from scorpion venom with pharmacodynamic activity of Alzheimer's disease (premature Alzheimer's disease) was separated by LaGM composite material and repeated rapid magnetic separation, and then performed parallel mass spectrometry using nanoliter reversed-phase chromatography-electrospray mass spectrometry (nanoLC-ESI-MS). A polypeptide sequence consisting of 15 amino acid residues was detected in the experiment; a heat-resistant synthetic peptide of scorpion venom was prepared through solid-phase chemical synthesis, chromatographic purification and mass spectrometry identification. Its amino acid sequence is shown in SEQIDNo 1, which maintains the The pharmacodynamic activity and safety of the scorpion venom heat-resistant peptide, and the bioactivity of the scorpion venom heat-resistant peptide also promotes the reverse differentiation of glial cells into neural stem cells.
Owner:上海万锦医药科技有限公司

Preparation and application of epilepsy animal model

The invention provides preparation and application of an intractable epilepsy animal model. Specifically, the invention provides a preparation method of an intractable epilepsy animal model of a non-human mammal, and the preparation method comprises the following steps: (1) providing a non-human mammal A and a non-human mammal B expressed by neuron cell specific Cre recombinase of the same species; wherein the genome of the non-human mammal A has (E1) an endogenous Cdkl5 gene and (E2) a conditional knockout element which is operatively connected with the Cdkl5 gene and is used for conditional knockout of the Cdkl5 gene, and the conditional knockout element is used for conditional knockout of the Cdkl5 gene of the genome of neuronal cells in the presence of the Cre recombinase, so that the Cdkl5 gene is inactivated; (2) carrying out mating breeding on the animal A and an animal B to obtain a filial generation non-human mammal C of which the Cdkl5 gene is specifically knocked out in neuronal cells; and (3) culturing the filial generation non-human mammal C to obtain the intractable epilepsy animal model. According to the invention, the curative effect of the anti-epilepsy drug can be preliminarily evaluated according to the change of spontaneous epilepsy phenotype of animals.
Owner:CENT FOR EXCELLENCE IN BRAIN SCI & INTELLIGENCE TECH CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products